AIDS

Article	Citations
Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study	120
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis	90
Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study	89
Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19	74
Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV	72
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV	70
Risk of adverse coronavirus disease 2019 outcomes for people living with HIV	67
HIV infection and COVID-19: risk factors for severe disease	62
Impaired antibody response to COVID-19 vaccination in advanced HIV infection	58
The Joint United Nations Programme on HIV/AIDS 95–95–95 targets: worldwide clinical and cost benefits of generic manufacture	54
Incident HIV among pregnant and breast-feeding women in sub-Saharan Africa: a systematic review and meta-analysis	51
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection	49
HIV in Iran: onset, responses, and future directions	46
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen	46
Productive HIV infection in astrocytes can be established via a nonclassical mechanism	40
Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes	40
Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV	40
Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM	37
Clinical characteristics, comorbidities and outcomes among persons with HIV hospitalized with coronavirus disease 2019 in Atlanta, Georgia	37
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV	37
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment	36
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV	36
Risk factors for loss to follow-up from antiretroviral therapy programmes in low-income and middle-income countries	34
The People Living with HIV Stigma Index 2.0: generating critical evidence for change worldwide	34
Antiretroviral drug concentrations in brain tissue of adult decedents	34

Community-based delivery of HIV treatment in Zambia: costs and outcomes	34
TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells	33
Worldwide relative smoking prevalence among people living with and without HIV	33
Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan	32
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen	31
Oral preexposure prophylaxis continuation, measurement and reporting	30
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials	30
High levels of genetically intact HIV in HLA-DR+ memory T cells indicates their value for reservoir studies	29
Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection	29
Increasing preexposure prophylaxis use and ‘net prevention coverage’ in behavioural surveillance of Australian gay and bisexual men	28
Modeling an integrated HIV prevention and care continuum to achieve the Ending the HIV Epidemic goals	27
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents	27
Frailty transitions, inflammation, and mortality among persons aging with HIV infection and injection drug use	27
Comparison of dementia risk after age 50 between individuals with and without HIV infection	26
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients	26
Factors associated with hospital admission for COVID-19 in HIV patients	25
Changes in weight and BMI with first-line doravirine-based therapy	25
Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events	25
Coronavirus disease 2019 attack rate in HIV-infected patients and in preexposure prophylaxis users	25
High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV – but HIV viremia matters?	24
Clinic-level and individual-level factors that influence HIV viral suppression in adolescents and young adults: a national survey in Kenya	24
Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis	24
Circulating extracellular vesicles as new inflammation marker in HIV infection	23
HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM	23
Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIV	23
Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era	22
Lung function in men with and without HIV	22
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV	22
Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint	22
Increased infectious-cause hospitalization among infants who are HIV-exposed uninfected compared with HIV-unexposed	22
Is tenofovir disoproxil fumarate associated with weight loss?	22
SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment	22
Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV	22
Longitudinal patterns of illicit drug use, antiretroviral therapy exposure and plasma HIV-1 RNA viral load among HIV-positive people who use illicit drugs	22
Projecting the impact of equity-based preexposure prophylaxis implementation on racial disparities in HIV incidence among MSM	21
A total facility approach to reducing HIV stigma in health facilities: implementation process and lessons learned	21
Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel	20
Association of HIV infection with outcomes among adults hospitalized with COVID-19	19
Household wealth and HIV incidence over time, rural Uganda, 1994–2018	19
Ending an HIV epidemic among persons who inject drugs in a middle-income country: extremely low HIV incidence among persons who inject drugs in Hai Phong, Viet Nam	19
Characteristics and clinical manifestations of monkeypox among people with and without HIV in the United States: a retrospective cohort	19
Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected	19
Investigation of factors associated with spontaneous preterm birth in pregnant women living with HIV	19
An updated meta-analysis on the association between HIV infection and COVID-19 mortality	18
Beta amyloid levels in cerebrospinal fluid of HIV-infected people vary by exposure to antiretroviral therapy	18
Viral suppression during COVID-19 among people with HIV experiencing homelessness in a low-barrier clinic-based program	18
Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose	18
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV	18
Hospital admissions in individuals with HTLV-1 infection in Spain	18
Progress toward HIV elimination goals: trends in and projections of annual HIV testing and condom use in Africa	18

Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis	18
The shifting age distribution of people with HIV using antiretroviral therapy in the United States	18
Exploring patterns and predictors of suicidal ideation among pregnant and postpartum women living with HIV in Kilimanjaro, Tanzania	18
Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV	18
The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa	18
Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV	17
The COVID-19 pandemic as a catalyst for differentiated care models to end the HIV epidemic in the United States: applying lessons from high-burden settings	17
Mapping the extent of heterogeneity of human CCR5+ CD4+ T cells in peripheral blood and lymph nodes	17
Clinic and care: associations with adolescent antiretroviral therapy adherence in a prospective cohort in South Africa	17
Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model	17
Impact of long-acting therapies on the global HIV epidemic	17
Early antiretroviral therapy-treated perinatally HIV-infected seronegative children demonstrate distinct long-term persistence of HIV-specific T-cell and B-cell memory	17
Structural determinants of HIV/STI prevalence, HIV/STI/sexual and reproductive health access, and condom use among immigrant sex workers globally	17
Incidence, clearance, persistence and factors related with high-risk anal HPV persistence in South-East Asian MSM and transgender women	17
Using longitudinal genetic-network study to understand HIV treatment-as-prevention	17
Accuracy of self-reported HIV-testing history and awareness of HIV-positive status in four sub-Saharan African countries	17
Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages	17
Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy	17
Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV	16
COVID-19 vaccine immunogenicity in people with HIV	16
Telemedicine and visit completion among people with HIV during the coronavirus disease 2019 pandemic compared with prepandemic	16
A taxonomy of pragmatic measures of HIV preexposure prophylaxis use	16
Decision-making regarding condom use among daily and event-driven users of preexposure prophylaxis in the Netherlands	16
Long noncoding RNA HOTAIRM1 promotes myeloid-derived suppressor cell expansion and suppressive functions through up-regulating HOXA1 expression during latent HIV infection	16
Effects of anticholinergic medication use on brain integrity in persons living with HIV and persons without HIV	16
Effects of an intervention on internalized HIV-related stigma for individuals newly entering HIV care	16
The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy	16
Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens	16
Performance of a short, self-report adherence scale in a probability sample of persons using HIV antiretroviral therapy in the United States	16
Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period	16
Sexually transmitted infections among African women: an opportunity for combination sexually transmitted infection/HIV prevention	16
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy	16
Potential impact of COVID-19 in people living with HIV: experience from previous 21st century coronaviruses epidemics	15
Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia	15
Intersectional stigmas and HIV-related outcomes among a cohort of key populations enrolled in stigma mitigation interventions in Senegal	15
Weight gain stopping/switch rules for antiretroviral clinical trials	15
Risk of HIV infection among adolescent girls and young women in age-disparate relationships in sub-Saharan Africa	15
Increase in HIV incidence in women exposed to rape	15
HIV disease duration, but not active brain infection, predicts cortical amyloid beta deposition	15
Declines in HIV prevalence in female sex workers accessing an HIV treatment and prevention programme in Nairobi, Kenya over a 10-year period	15
Curable sexually transmitted infections among women with HIV in sub-Saharan Africa	15
Variation in estimated viral suppression associated with the definition of viral suppression used	15
Markers of inflammation and immune activation are associated with lung function in a multi-center cohort of persons with HIV	15
Incident infection in high-priority HIV molecular transmission clusters in the United States	15
High abundance of genus Prevotella is associated with dysregulation of IFN-I and T cell response in HIV-1-infected patients	15
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV	14
Genetically-edited induced pluripotent stem cells derived from HIV-1-infected patients on therapy can give rise to immune cells resistant to HIV-1 infection	14
False-positive HIV screening test in a patient with pulmonary embolism because of severe acute respiratory syndrome coronavirus 2 infection	14
HIV influences microtubule associated protein-2: potential marker of HIV-associated neurocognitive disorders	14
Advanced HIV disease in the Botswana combination prevention project: prevalence, risk factors, and outcomes	14
SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV	14
Low CD4+ cell count nadir exacerbates the impacts of APOE ε4 on functional connectivity and memory in adults with HIV	14
Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era	14
Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options	14
Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment	14
Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa	14
Impact of HIV infection on baseline characteristics and survival of women with breast cancer	14
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV	14
Differential impact of antiretroviral therapy initiated before or during pregnancy on placenta pathology in HIV-positive women	13
Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents	13
Increased monocyte and T-cell activation in treated HIV+ Ugandan children: associations with gut alteration and HIV factors	13
Assessing comorbidities and survival in HIV-infected and uninfected matched Medicare enrollees	13
Limitations of the UNAIDS 90-90-90 metrics: a simulation-based comparison of cross-sectional and longitudinal metrics for the HIV care continuum	13
Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine	13
Associations between methamphetamine use and lack of viral suppression among a cohort of HIV-positive persons who inject drugs in Hai Phong, Vietnam	13
Semen virome of men with HIV on or off antiretroviral treatment	13
Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa	13
Multimorbidity networks associated with frailty among middle-aged and older people with HIV	13
Employing telehealth within HIV care: advantages, challenges, and recommendations	13
Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV	13
Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation	13
Higher prevalence of stunting and poor growth outcomes in HIV-exposed uninfected than HIV-unexposed infants in Kenya	13
Evaluation of the POP-UP programme: a multicomponent model of care for people living with HIV with homelessness or unstable housing	13
HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health	12
Novel population-level proxy measures for suboptimal HIV preexposure prophylaxis initiation and persistence in the USA	12
Severe intimate partner violence is associated with all-cause mortality among women living with HIV	12
Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection	12
Internalized HIV stigma predicts subsequent viremia in US HIV patients through depressive symptoms and antiretroviral therapy adherence	12
Sterol metabolism modulates susceptibility to HIV-1 Infection	12
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1	12

Trends in diabetes incidence and associated risk factors among people with HIV in the current treatment era	12
A comparative study of classic and HIV-viremic and aviremic AIDS Kaposi sarcoma	12
Modeling the cost-effectiveness of point-of-care platforms for infant diagnosis of HIV in sub-Saharan African countries	12
Utilizing electronic health record data to understand comorbidity burden among people living with HIV: a machine learning approach	12
Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection	12
The effect of universal testing and treatment on HIV stigma in 21 communities in Zambia and South Africa	12
Tuberculosis symptom screening for children and adolescents living with HIV in six high HIV/TB burden countries in Africa	12
Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain	12
HIV-1 viral blips are associated with repeated and increasingly high levels of cell-associated HIV-1 RNA transcriptional activity	12
Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV	12
Psychiatric trajectories across adolescence in perinatally HIV-exposed youth: the role of HIV infection and associations with viral load	11
A systematic review of early adoption of implementation science for HIV prevention or treatment in the United States	11
Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish elite control in adolescents living with HIV from viremic nonprogressors	11
Performing rapid autopsy for the interrogation of HIV reservoirs	11
Achieving maternal viral load suppression for elimination of mother-to-child transmission of HIV in South Africa	11
Longitudinal association between intimate partner violence and viral suppression during pregnancy and postpartum in South African women	11
Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV	11
Depression and HIV viral nonsuppression among people engaged in HIV care in an urban clinic, 2014–2019	11
Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens	11
HIV stigma by association among Australian gay and bisexual men	11
Comparison of dementia incidence and prevalence between individuals with and without HIV infection in primary care from 2000 to 2016	11
Losartan to reduce inflammation and fibrosis endpoints in HIV disease	11
What shapes resilience among people living with HIV? A multi-country analysis of data from the PLHIV Stigma Index 2.0	11
Cognitive trajectories after treatment in acute HIV infection	11
First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines	11
HIV-1 infection of the kidney: mechanisms and implications	11
Machine-learning classification of neurocognitive performance in children with perinatal HIV initiating de novo antiretroviral therapy	11
Internalized stigma among people living with HIV: assessing the Internalized AIDS-Related Stigma Scale in four countries	11
Estimated time from HIV infection to diagnosis and diagnosis to first viral suppression during 2014–2018	11
Infection of severe acute respiratory syndrome coronavirus 2 in a patient with AIDS	11
Using HIV self-testing to increase the affordability of community-based HIV testing services	10
Application of machine-learning techniques in classification of HIV medical care status for people living with HIV in South Carolina	10
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis	10
HIV/AIDS and aging: the new frontier for HIV/AIDS research and care	10
Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysis	10
Impact of the coronavirus disease 2019 pandemic on prescriptions for antiretroviral drugs for HIV treatment in the United States, 2019–2021	10
Antiretroviral therapy-treated HIV-infected adults with coronary artery disease are characterized by a distinctive regulatory T-cell signature	10
Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes	10
Monocyte activation in persons living with HIV and tuberculosis coinfection	10
Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV	10
Incidence of HIV-positive admission and inpatient mortality in Malawi (2012–2019)	10
The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa	10
Integration and scale-up of efforts to measure and reduce HIV-related stigma: the experience of Thailand	10
Measuring retention in HIV care: the impact of data sources and definitions using routine data	10
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa	10
Severe acute respiratory syndrome coronavirus-2 antibody prevalence in people with and without HIV in rural Western Kenya, January to March 2020	10
First pharmacokinetic data of bictegravir in pregnant women living with HIV	10
Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression	10
Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis	10
Assessing self-reported discrimination among men who have sex with men (MSM)	10
Syndemics and preexposure prophylaxis are independently associated with rectal immune dysregulation in sexual minority men	10
Aging, trends in CD4+/CD8+ cell ratio, and clinical outcomes with persistent HIV suppression in a dynamic cohort of ambulatory HIV patients	10
Financial incentives to increase pediatric HIV testing: a randomized trial	10
Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV	10
Estimating the probability of diagnosis within 1 year of HIV acquisition	10
Stigma among key populations living with HIV in the Dominican Republic: experiences of people of Haitian descent, MSM, and female sex workers	10
A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV	10
Global estimates for the lifetime cost of managing HIV	10
HIV and risk of dementia in older veterans	10
Direct maternal deaths attributable to HIV in the era of antiretroviral therapy: evidence from three population-based HIV cohorts with verbal autopsy	10
Distinct forms of migration and mobility are differentially associated with HIV treatment adherence	10
Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya	10
Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients	10
Circulating microRNA signatures that predict liver fibrosis progression in patients with HIV-1/hepatitis C virus coinfections	10
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria	10
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoprox	10
Deciphering the serological response to syphilis treatment in men living with HIV	9
Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States	9
Predictors of secondary HIV transmission risk in a cohort of adolescents living with HIV in South Africa	9
Determining standardized causes of death of infants, children, and adolescents living with HIV in Asia	9
Risk factors and outcomes of HIV-associated stroke in Zambia	9
A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration	9
Immature/transitional B-cell expansion is associated with bone loss in HIV-infected individuals with severe CD4+ T-cell lymphopenia	9
Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individuals	9
Mathematical modelling of the influence of serosorting on the population-level HIV transmission impact of pre-exposure prophylaxis	9
Tenofovir-based PrEP for COVID-19: an untapped opportunity?	9
Challenges to achieving and maintaining viral suppression among children living with HIV	9
Changes in HIV preexposure prophylaxis prescribing in Australian clinical services following COVID-19 restrictions	9
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir	9
Circulating CD4+ TEMRA and CD4+ CD28− T cells and incident diabetes among persons with and without HIV	9
Children who are HIV-exposed and uninfected: evidence for action	9
Interactive digital interventions for prevention of sexually transmitted HIV	9
What are the situational and behavioral factors associated with condomless anal sex without pre-exposure prophylaxis in MSM?	9
SARS-CoV-2 infection in a highly experienced person living with HIV	9
Drug efflux transporters and metabolic enzymes in human circulating and testicular T-cell subsets: relevance to HIV pharmacotherapy	9
Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV	9
The other side of screening: predictors of treatment and follow-up for anal precancers in a large health system	9
The predictors of pain extent in people living with HIV	9
Growth deficits in antiretroviral and HIV-exposed uninfected versus unexposed children in Malawi and Uganda persist through 60 months of age	9
Effect of Truvada lawsuit advertising on preexposure prophylaxis attitudes and decisions among sexual and gender minority youth and young adults at risk for HIV	9
Depot medroxyprogesterone acetate administration increases cervical CCR5+CD4+ T cells and induces immunosuppressive milieu at the cervicovaginal mucosa	9
Interventions to improve daily medication use among adolescents and young adults: what can we learn for youth pre-exposure prophylaxis services?	9
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients	9
Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1-infected patients	9
Legacy effect on neuropsychological function in HIV-infected men on combination antiretroviral therapy	9